Skip to main content

CARACTERIZACION FENOTIPICA PARA DETERMINAR LA VARIABILIDAD INDIVIDUAL DE LA PROGRESION DE LA FIBROSIS EN LA ESTEATOHEPATITIS NO ALCOHOLICA

PI19/01404

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
Execution centre INSTITUTO DE BIOMEDICINA DE SEVILLA - IBIS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Emerging pharmacological treatment options for MAFLD

  • Rojas, Ángela
  • Lara-Romero, Carmen
  • Muñoz-Hernández, Rocío
  • Gato, Sheila
  • Ampuero, Javier
  • Romero-Gómez, Manuel
Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension, hypertriglyceridemia, hypercholesterolemia, insulin resistance, and cardiovascular risk, increasing the risk of mortality. The excessive accumulation of fat comprises apoptosis, necrosis, inflammation and ballooning degeneration progressing to fibrosis, cirrhosis, and liver decompensations including hepatocellular carcinoma development. The limitation of approved drugs to prevent MAFLD progression is a paradigm. This review focuses on recent pathways and targets with evidence results in phase II/III clinical trials., Ministerio de Ciencia y Competitividad under grant agreements PI19/01404 and PI19/00589. A contract with fellowship from Consejería de Salud y Familias, Junta de Andalucía, supporting Angela Rojas (RH-002-2021); grant agreements PFIS FI20/00201 from Instituto de Salud Carlos III to support Sheila Gato and by support from Talento Doctores (PID Junta Andalucía, DOC_00866) to Rocío Muñoz-Hernández., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies

  • Rojas, Ángela
  • García-Lozano, María del Rosario
  • Gil-Gómez, Antonio
  • Romero-Gómez, Manuel
  • Ampuero, Javier
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide, reflecting the current epidemics of obesity, insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. NAFLD is characterized by the accumulation of fat in the liver, and is known to be a cause of cirrhosis. Although many pathways have been proposed, the cause of NAFLD-linked fibrosis progression is still unclear, which posed challenges for the development of new therapies to prevent NASH-related cirrhosis and hepatocellular carcinoma. Cirrhosis is associated with activation of hepatic stellate cells (HSC) and accumulation of excess extracellular matrix proteins, and inhibiting the activation of HSCs would be expected to slow the progression of NAFLD-cirrhosis. Multiple molecular signals and pathways such as oxidative stress and glutaminolysis have been reported to promote HSC activation. Both mechanisms are plausible antifibrotic targets in NASH, as the activation of HSCs the proliferation of myofibroblasts depend on those processes. This review summarizes the role of the glutaminolysis-ammonia-urea cycle axis in the context of NAFLD progression, and shows how the axis could be a novel therapeutic target., This project was funded in part by the Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III (PI19/00589, PI19/01404, PI16/01842, PI17/00535 and GLD19/00100). Ángela Rojas has received the Sara Borrell postdoctoral fellowships from Instituto de Salud Carlos III CD18/00126 to support her postdoctoral contract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD

  • Ampuero, Javier
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Montero, Rocío
  • Gato, Sheila
  • Rojas, Ángela
  • Gil, Antonio
  • Muñoz, Rocío
  • Romero-Gómez, Manuel
[Background] NAFLD clinical trials have shown suboptimal results, particularly for liver fibrosis, despite the robust preclinical drug development. We aimed to assess the histological response after the experimental treatment versus placebo by carrying out a meta-analysis of NAFLD clinical trials., [Methods] After a systematic review of NAFLD clinical trials to May 2021, applying strict selection criteria, the following primary outcomes were observed: (a) NASH resolution, with no worsening of fibrosis when available; (b) fibrosis improvement  ≥ 1 stage, with no worsening of NAS when available; (c) worsening of NAS; (d) worsening of liver fibrosis  ≥ 1 stage, including the progression to cirrhosis on histopathology. Other histological, clinical, and biochemical outcomes were considered secondary endpoints. Heterogeneity was explored by subgroup and sensitivity analyses, and univariable meta-regression., [Results] Twenty-seven randomized clinical trials were included. The pooled efficacy for NASH resolution receiving experimental therapy was 19% (95%CI 15–23; I2 96.2%) compared with placebo 10% (95%CI 7–12; I2 85.8%) (OR 1.66 (95%CI 1.24–2.21); I2 57.8%), while it was 26% (95%CI 22–29); I2 90%)) versus 18% (95%CI 15–21; I2 59%)) for fibrosis improvement (OR 1.34 (95%CI 1.13–1.58); I2 25.4%). For these outcomes, the therapy showed higher efficacy in trials longer than 48 weeks, with  < 60% of diabetic population, and when it targeted FXR, PPAR, and antidiabetic mechanisms, and with a NAS  < 5 for NASH resolution. Also, NASH (OR 0.57 (95%CI 0.39–0.84); I2 67%) and fibrosis worsening (OR 0.65 (95%CI 0.46–0.92); I2 61.9%) were prevented with the therapy., [Conclusion] This meta-analysis provides information about the efficacy of the therapy versus placebo by comparing different and combined trial outcomes such as NASH resolution, fibrosis improvement, and NAS and fibrosis worsening. Changes in the experimental design and selection criteria of the clinical trials might be suitable to increase the efficacy., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This project has been partially funded by the “Consejería de Salud de la Junta de Andalucía” (PI-0075–2014), the “Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III” (PI16/01842, PI17/00535, PI19/01404, PI19/00589, IFI18/00041 and GLD19/00100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses

  • García-Lozano, María del Rosario
  • Dragoni, Filippo
  • Gallego, Paloma
  • Mazzotta, Sarah
  • López-Gómez, Alejandro
  • Boccuto, Adele
  • Martínez-Cortés, Carlos
  • Rodríguez-Martínez, Alejandro
  • Pérez-Sánchez, Horacio
  • Vega-Pérez, José Manuel
  • Campo, José A. del
  • Vicenti, Ilaria
  • Vega-Holm, Margarita
  • Iglesias-Guerra, Fernando
© 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., Since 2011 Direct Acting antivirals (DAAs) drugs targeting different non-structural (NS) viral proteins (NS3, NS5A or NS5B inhibitors) have been approved for clinical use in HCV therapies. However, currently there are not licensed therapeutics to treat Flavivirus infections and the only licensed DENV vaccine, Dengvaxia, is restricted to patients with preexisting DENV immunity. Similarly to NS5 polymerase, the NS3 catalytic region is evolutionarily conserved among the Flaviviridae family sharing strong structural similarity with other proteases belonging to this family and therefore is an attractive target for the development of pan-flavivirus therapeutics. In this work we present a library of 34 piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. The library was developed through a privileged structures-based design and then biologically screened using a live virus phenotypic assay to determine the half-maximal inhibitor concentration (IC50) of each compound against ZIKV and DENV. Two lead compounds, 42 and 44, with promising broad-spectrum activity against ZIKV (IC50 6.6 µM and 1.9 µM respectively) and DENV (IC50 6.7 µM and 1.4 µM respectively) and a good security profile were identified. Besides, molecular docking calculations were performed to provide insights about key interactions with residues in NS3 proteases’ active sites., This work has been supported by Ministerio de Ciencia, Innovación y Universidades, Plan Estatal 2017-2020 Retos - Proyectos I + D + i (PID2019-104767RB-I00). MRGL also thanks Ministerio de Economía y Competitividad, Instituto de Salud Carlos III (grants PI19/00589, PI19/01404, PI16/01842, PI17/00535 and GLD19/00100) for financial support., This work was supported by funds from MIUR Ministero dell’Istruzione, dell’Università della Ricerca Italiano, project PRIN 2017, ORIGINALE CHEMIAE in Antiviral Strategy—Origin and Modernization of Multi-Component Chemistry as a Source of Innovative Broad-Spectrum Antiviral Strategy (cod. 2017BMK8JR) and from Tuscany region, project Tuscany Antiviral Research Network -TUSCAVIR.NET (Bando Ricerca Salute 2018). We would like to thank Giulietta Venturi for making the ZIKV H/PF/2013 strain available for this study., This work has also been funded by the Fundación Séneca de la Región de Murcia under Project 20988/PI/18., This research was partially supported by the computer resources and the technical support provided by the supercomputing infrastructure of the NLHPC (ECM-02), Powered@NLHPC and the Extremadura Research Centre for Advanced Technologies (CETA − CIEMAT), funded by the European Regional Development Fund (ERDF). CETA − CIEMAT is part of CIEMAT and the Government of Spain., Authors thank CITIUS (Centro de Investigación, Tecnología e Innovación de la Universidad de Sevilla) for its important contribution in recording NMR and Mass spectra and in elemental analysis determination., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells

  • Guillén-Mancina, Emilio
  • García-Lozano, María del Rosario
  • Burgos-Morón, Estefanía
  • Mazzotta, Sarah
  • Martínez-Aguado, Pablo
  • Calderón-Montaño, José Manuel
  • Vega-Pérez, José Manuel
  • López-Lázaro, Miguel
  • Iglesias-Guerra, Fernando
  • Vega-Holm, Margarita
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Breast cancer is the most common type of cancer in women. Although current treatments can increase patient survival, they are rarely curative when the disease is advanced (metastasis). Therefore, there is an urgent need to develop new cytotoxic drugs with a high selectivity toward cancer cells. Since repurposing approved drugs for cancer therapy has been a successful strategy in recent years, in this study, we screened a library of antiviral piperazine-derived compounds as anticancer agents. The compounds included a piperazine ring and aryl urea functions, which are privileged structures present in several anti-breast cancer drugs. The selective cytotoxic activity of a set of thirty-four 4-acyl-2-substituted piperazine urea derivatives against MCF7 breast cancer cells and MCF 10A normal breast cells was determined. Compounds 31, 32, 35, and 37 showed high selective anticancer activity against breast cancer cells and were also tested against another common type of cancer, non-small cell lung cancer (A549 lung cancer cells versus MRC-5 lung normal cells). Compounds 35 and 37 also showed selectivity against lung cancer cells. These results suggest that compounds 35 and 37 may be promising hit compounds for the development of new anticancer agents., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Plan Estatal 2017-2020 Retos-Proyectos I + D + i (PID2019-104767RB-I00). M.d.R.G.-L. also thanks Ministerio de Economía y Competitividad, Instituto de Salud Carlos III (grants PI19/00589, PI19/01404, PI16/01842, PI17/00535, and GLD19/00100) for financial support. Additional support was given by Junta de Andalucía (grant numbers 2017/CTS-657 and 2019/CTS-657) and the University of Seville through the “V Plan Propio de Investigación y Transferencia” (grant number PPI2015-II.2), the “VI Plan Propio de Investigación y Transferencia” (grant numbers VIPPIT-2019-I.5 and VIPPIT-2020-I.5) and the “VII Plan Propio de Investigación y Transferencia” (grant number VIIPPIT-2023-I.3)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial

  • Giráldez, Álvaro
  • Rodríguez-Seguel, Elisa
  • Valencia Martín, Raquel
  • Morillo, Áurea
  • Salamanca-Rivera, Celia
  • Ruiz-Pérez, Ricardo
  • Cuaresma-Duque, María
  • Rosso-Fernández, Clara
  • Ferrer-Ríos, María Teresa
  • Sousa-Martín, José Manuel
  • Praena-Fernández, Juan Manuel
  • Desongles-Corrales, Trinidad
  • Rodríguez-Pérez, Aitana
  • Camino-Durán, Francisco
  • Gasch-Illescas, Antonia
  • Ampuero, Javier
  • Pascasio, Juan Manuel
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ., [Objective] We aimed to compare the response rates between two different hepatitis B virus vaccination schedules for cirrhotic subjects who were non-responders to the first three 40 µg doses (month 0-1-2), and identify factors associated with the final response., [Design] A total of 120 cirrhotic patients (72.5% decompensated) were randomised at a 1:1 ratio to receive a single 40 µg booster vaccination at month 6 (classical arm) versus an additional round of three new 40 µg doses administered at monthly intervals (experimental arm). The main outcome was the rate of postvaccinal anti-hepatitis B surface antibodies levels ≥10 mIU/mL., [Results] Efficacy by ITT analysis was higher in the experimental arm (46.7%) than in the classical one (25%); OR 2.63, p=0.013. The experimental arm increased response rates compared with the classical one from 31% to 68% (OR 4.72; p=0.007), from 24.4% to 50% (OR 3.09; p=0.012) and from 24.4% to 53.8% (OR 3.62; p=0.007), in Child A, Model for End-Stage Liver Disease (MELD) <15 and MELD-Na<15 patients, respectively. Patients with more advanced liver disease did not benefit from the reinforced scheme. Both regimens showed similar safety profiles. Multivariable analysis showed that the experimental treatment was independently response associated when adjusted across three logistic regression models indicating equivalent cirrhosis severity., [Conclusion] For cirrhotic patients, the revaccination of non-responders to the first three dose cycle, with three additional 40 µg doses, achieved significantly better response rates to those obtained with an isolated 40 µg booster dose., [Trial registration number] NCT01884415., This study project was awarded competitive public funding for Independent Research from the Spanish Government Ministry of Health and Social Politics in 2011 via the Carlos III Health Institute (EC11-452). Javier Ampuero is supported by grants from the Carlos III Health Institute (GLD19/00100 and PI19/01404). IBiS was created as a partnership between the Junta of Andalusia Department of Health, the Department of Innovation, Science and Business of the Junta of Andalusia, the Andalusian Health Service, the University of Seville and the Spanish National Research Council., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel insights into metabolic-associated steatotic liver disease preclinical models

  • Montero-Vallejo, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Martín, Franz
  • Romero-Gómez, Manuel
  • Gallego-Durán, Rocío
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims., The research leading to these results has received funding from the Consejería de Salud de la Junta de Andalucía under grant agreement PC-0148-2016-0148 and PE-0451-2018, and from the Instituto de Salud Carlos III under grant agreements CD21/00095, PI19/01404, PI19/00589, PI22/01342, PI22/01345 and IFI18/00041 and Ministerio de Economía y Competitividad under grant agreement AGL-2017-86927-R and PID2020-116731RB-C21. Rocío Montero-Vallejo has received the Juan Manuel Herrerías from Sociedad Andaluza de Patología Digestiva, CIBERehd grants to support mobility and improve mice handling. Rocío Gallego-Durán has received the Andrew K Burroughs Fellowship from European Association for the Study of the Liver (EASL), Aprendizaje de Nuevas Tecnologías fellowship from Asociación Española para el Estudio del Hígado (AEEH) and CIBERehd Grant to support researcher's mobility., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C

  • Sánchez-Torrijos, Yolanda
  • Fernández-Álvarez, Paula
  • Rosales, José Miguel
  • Pérez-Estrada, Celia
  • Alañón-Martínez, Paloma
  • Rodríguez-Perálvarez, Manuel L.
  • Jimeno, Carlota
  • Pino Bellido, Pilar del
  • García-García, Alberto
  • López-Garrido, Ángeles
  • García-Cortés, Miren
  • Romero, Gema
  • Romero-Gómez, Manuel
  • Casado, Marta
  • Carmona Soria, Isabel
  • Ampuero, Javier
Referred to by: Advancing our understanding of recompensated cirrhosis - the new “holy grail” of decompensated cirrhosis, https://doi.org/10.1016/j.jhep.2025.04.014, [Backgound & Aims] The Baveno VII consensus introduced the term “recompensated cirrhosis,” though few studies have examined its clinical relevance. We analyzed the rate and predictors of recompensation after sustained virological response (SVR) in patients with HCV and evaluated its impact on mortality and hepatocellular carcinoma (HCC) compared to compensated and decompensated cirrhosis., [Methods] We performed a multicenter observational study enrolling 916 patients with HCV-related cirrhosis with a minimum follow-up period of 12 months after SVR. Patients were categorized into three mutually exclusive groups: compensated, decompensated, and recompensated. Patients were followed until the occurrence of liver transplantation, death, or the last follow-up date, whichever came first., [Results] During the study (4.5 ± 2.5 years), 12% (110/916) experienced a decompensating event, 7.7% (71/916) were diagnosed with HCC, and 14.9% (137/916) died. Among the 23% (216/916) of patients who were decompensated at baseline, 63.4% (137/216) achieved recompensation at 12 months. Child-Pugh score (odds ratio 0.69; 95% CI 0.53-0.89; p = 0.005) and the number of past decompensating events were associated with recompensation. The compensated cohort exhibited a lower mortality rate (4.2% [28/663]) than recompensated (36.5% [50/137]) and decompensated (50% [30/60]) patients (p = 0.0001). Along with age (cause-specific hazard ratio [CSHR] 1.03; 95% CI 1.01-1.05; p = 0.0009), albumin (CSHR 0.67; 95% CI 0.45-0.98; p = 0.038), international normalized ratio (CSHR 1.88; 95% CI 1.14-3.10; p = 0.014), and bilirubin levels (CSHR 1.28; 95% CI 1.08-1.50; p = 0.003), recompensated (CSHR 0.30; 95% CI 0.19-0.49; p = 0.0001) and compensated (CSHR 0.09; 95% CI 0.05-0.16; p = 0.0001) states were associated with mortality. By contrast, HCC occurrence was significantly lower in compensated (4.4% [29/662]) than recompensated (14.4% [19/132]) and decompensated (12.1% [7/58]) patients (p = 0.0001)., [Conclusions] Two-thirds of patients with decompensated cirrhosis achieved recompensation 12 months after SVR. Survival was better in recompensated patients than in decompensated patients, but still worse than in compensated patients. However, HCC risk remained unchanged in the recompensated cohort., This project has been partially funded by the “Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III” (PI19/01404, PI16/01842, PI17/00535 and GLD19/00100) and co-funded by the European Union. ∗The funders have not had any role in the design, analysis, writing, or interpretation of this project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mechanistic insights into the liver-brain axis during chronic liver disease

  • Siddle, Matthew
  • Gallego-Durán, Rocío
  • Goel, Deepika
  • Renquist, Benjamin J.
  • Holt, Marie K.
  • Hadjihambi, Anna
The liver is a metabolically flexible tissue, adapting its functions to changes in nutrient availability and physiological states. This adaptability is crucial for maintaining metabolic homeostasis and likely involves communication with the central nervous system through the liver–brain axis. The liver also receives a constant influx of nutrients, hormones and microbial metabolites from the gastrointestinal tract in a multifaceted communication network, the gut–liver–brain axis. Dysregulation of this communication can lead to hepatic encephalopathy and cognitive impairments in early-stage chronic liver disease, such as metabolic dysfunction-associated steatotic liver disease, substantially affecting patient quality of life. This Review examines key signalling pathways along the liver–brain axis: humoral signalling, including metabolites, hepatokines, toxins and inflammation, and neural pathways, focusing on afferent signalling through the common hepatic branch of the vagus nerve. We discuss how each pathway might contribute to behavioural and mood changes in chronic liver disease and the development of hepatic encephalopathy. Although the humoral effects have been studied more extensively, we propose that the afferent vagus nerve is central to liver disease-associated cognitive and behavioural complications. Finally, we highlight how new techniques and tools could advance our understanding of the gut–liver–brain communication that affects behaviour., M.S. is funded by the Wellcome Trust as part of the Neuro-Immune Interactions in Health & Disease Wellcome Trust PhD Programme (218452/Z/19/Z). R.G.D. acknowledges support to ISCIII from grants CD21/00095, PI22/01342, PI19/01404, PI24/02008. B.J.R. is funded by the NIH (NIDDK R01DK132281) and the US Department of Defense (W81XWH-22-2-0043 and PR221455 HT9425-23-1-0810). M.K.H. is funded by the British Heart Foundation (FS/IPBSRF/20/27001) and the Royal Society (RG\R1\241213). A.H. is funded by UKRI, Future Leaders Fellowship (MR/X033287/1) and the Foundation for Liver Research., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detailed stratified GWAS analysis for severe COVID-19 in four European populations

  • Degenhardt, Frauke|||0000-0001-7516-3179
  • Ellinghaus, David|||0000-0002-4332-6110
  • Juzenas, Simonas
  • Lerga Jaso, Jon|||0000-0003-4807-1900
  • Wendorff, Mareike
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Uellendahl-Werth, Florian
  • ElAbd, Hesham
  • Rühlemann, Malte C.
  • Arora, Jatin
  • Özer, Onur
  • Lenning, Ole Bernt
  • Myhre, Ronny
  • Vadla, May Sissel
  • Wacker, Eike M.
  • Wienbrandt, Lars|||0000-0001-5685-2032
  • Blandino Ortiz, Aaron|||0000-0002-3184-6418
  • de Salazar, Adolfo|||0000-0002-4318-858X
  • Garrido Chercoles, Adolfo
  • Palom, Adriana|||0000-0002-0130-1302
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Garcia-Fernandez, Alba-Estela|||0000-0003-4957-0373
  • Blanco-Grau, Albert|||0000-0002-4213-3827
  • Mantovani, Alberto
  • Zanella, Alberto
  • Holten, Aleksander Rygh
  • Mayer, Alena
  • Bandera, Alessandra
  • Cherubini, Alessandro
  • Protti, Alessandro|||0000-0002-0172-6079
  • Aghemo, Alessio
  • Gerussi, Alessio
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Braun, Alice|||0000-0003-1145-0261
  • Nebel, Almut
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Lleo, Ana
  • Teles, Ana
  • Kildal, Anders Benjamin|||0000-0002-1319-6511
  • Biondi, Andrea
  • Caballero, Andrea|||0000-0003-2891-6347
  • Ganna, Andrea|||0000-0002-8147-240X
  • Gori, Andrea|||0000-0001-6587-4794
  • Glück, Andreas
  • Lind, Andreas
  • Tanck, Anja
  • Hinney, Anke|||0000-0001-5659-0706
  • Carreras Nolla, Anna|||0000-0002-8789-067X
  • Fracanzani, Anna Ludovica
  • Peschuck, Anna
  • Cavallero, Annalisa
  • Dyrhol-Riise, Anne Ma
  • Ruello, Antonella
  • Julià Cano, Antonio|||0000-0001-6064-3620
  • Muscatello, Antonio
  • Pesenti, Antonio|||0000-0003-2593-729X
  • Voza, Antonio
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Solier, Aurora
  • Schmidt, Axel|||0000-0002-9780-7243
  • Cortés, Beatriz|||0000-0002-2656-7051
  • Mateos Muñoz, Beatriz|||0000-0003-0326-4119
  • Nafria-Jimenez, Beatriz|||0000-0002-4698-5680
  • Schaefer, Benedikt
  • Jensen, Björn
  • Bellinghausen, Carla
  • Maj, Carlo
  • Ferrando, Carlos|||0000-0002-1907-5323
  • de la Horra, Carmen
  • Quereda, Carmen
  • Skurk, Carsten
  • Thibeault, Charlotte
  • Scollo, Chiara
  • Herr, Christian
  • Spinner, Christoph D.|||0000-0002-3875-5367
  • Gassner, Christoph
  • Lange, Christoph|||0000-0002-9691-4741
  • Hu, Cinzia
  • Paccapelo, Cinzia
  • Lehmann, Clara
  • Angelini, Claudio
  • Cappadona, Claudio
  • Azuure, Clinton
  • Bianco, Cristiana
  • Cea López, Cristina|||0000-0003-0776-6706
  • Sancho, Cristina
  • Hoff, Dag Arne Lihaug
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Prati, Daniele|||0000-0002-2281-7498
  • Haschka, David
  • Jiménez, David|||0000-0002-4571-7721
  • Pestaña, David
  • Toapanta, David
  • Muñíz Díaz, Eduardo
  • Azzolini, Elena
  • Sandoval, Elena|||0000-0002-4242-5133
  • Binatti, Eleonora
  • Scarpini, Elio|||0000-0002-6395-2119
  • Helbig, Elisa T.
  • Casalone, Elisabetta
  • Urrechaga, Eloisa
  • Paraboschi, Elvezia Maria|||0000-0002-7935-798X
  • Pontali, Emanuele|||0000-0002-1085-0442
  • Reverter, Enric|||0000-0002-4967-6947
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Navas, Enrique|||0000-0001-9561-1338
  • Solligård, Erik
  • Contro, Ernesto
  • Arana-Arri, Eunate|||0000-0001-9759-333X
  • Aziz, Fátima
  • Garcia, Federico
  • García Sánchez, Félix|||0000-0002-6965-5940
  • Ceriotti, Ferruccio|||0000-0002-0958-5354
  • Martinelli-Boneschi, Filippo
  • Peyvandi, Flora|||0000-0001-7423-9864
  • Kurth, Florian
  • Blasi, Francesco|||0000-0002-2285-9970
  • Malvestiti, Francesco
  • Medrano, Francisco J.
  • Mesonero, Francisco|||0000-0002-7864-8187
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Hanses, Frank
  • Müller, Fredrik
  • Hemmrich-Stanisak, Georg
  • Bellani, Giacomo
  • Grasselli, Giacomo|||0000-0002-1735-1400
  • Pezzoli, Gianni
  • Costantino, Giorgio
  • Albano, Giovanni
  • Cardamone, Giulia
  • Bellelli, Giuseppe
  • Citerio, Giuseppe|||0000-0002-5374-3161
  • Foti, Giuseppe
  • Lamorte, Giuseppe
  • Matullo, Giuseppe
  • Baselli, Guido
  • Kurihara, Hayato
  • Neb, Holger
  • My, Ilaria
  • Kurth, Ingo|||0000-0002-5642-8378
  • Hernández, Isabel|||0000-0001-8119-393X
  • Pink, Isabell
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Galván-Femenía, Iván|||0000-0002-6124-3730
  • Holter, Jan Cato
  • Afset, Jan Egil
  • Heyckendorf, Jan|||0000-0003-4203-8421
  • Kässens, Jan
  • Damås, Jan Kristian
  • Rybniker, Jan
  • Altmüller, Janine|||0000-0003-4372-1521
  • Ampuero, Javier|||0000-0002-8332-2122
  • Martín, Javier|||0000-0002-2202-0622
  • Erdmann, Jeanette|||0000-0002-4486-6231
  • Banales, Jesus|||0000-0002-5224-2373
  • Badia, Joan Ramon
  • Dopazo, Joaquín|||0000-0003-3318-120X
  • Schneider, Jochen
  • Bergan, Jonas|||0000-0003-4267-8904
  • Barretina, Jordi|||0000-0002-3478-4080
  • Walter, Jörn
  • Hernández Quero, José
  • Goikoetxea, Josune
  • Delgado Cuesta, Juan|||0000-0002-5947-6287
  • Guerrero, Juan M.
  • Fazaal, Julia
  • Kraft, Julia|||0000-0001-7306-1179
  • Schröder, Julia
  • Risnes, Kari
  • Banasik, Karina|||0000-0003-2489-2499
  • Müller, Karl Erik
  • Gaede, Karoline I.
  • Garcia-Etxebarria, Koldo
  • Tonby, Kristian
  • Heggelund, Lars
  • Izquierdo-Sanchez, Laura
  • Bettini, Laura Rachele|||0000-0002-0280-1704
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Sander, Leif Erik
  • Lippert, Lena J.
  • Terranova, Leonardo
  • Nkambule, Lindokuhle
  • Knopp, Lisa
  • Gustad, Lise Tuset
  • Garbarino, Lucia
  • Santoro, Luigi
  • Téllez, Luis|||0000-0002-9254-3891
  • Roade, Luisa|||0000-0002-8160-9613
  • Ostadreza, Mahnoosh
  • Intxausti, Maider
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Berger, Marc M.
  • Schaefer, Marco
  • Niemi, Mari E. K.
  • Gutiérrez-Stampa, María Ángeles
  • Carrabba, Maria
  • Figuera Basso, Maria E.
  • Valsecchi, Maria Grazia
  • Hernández Tejero, María|||0000-0002-6782-9150
  • Vehreschild, Maria J. G. T.
  • Manunta, Maria|||0000-0002-1875-5335
  • Acosta-Herrera, Marialbert|||0000-0002-9868-6535
  • D'Angio, Mariella|||0000-0001-7889-8576
  • Baldini, Marina
  • Cazzaniga, Marina Elena|||0000-0003-1756-6935
  • Grimsrud, Marit M.
  • Cornberg, Markus|||0000-0002-9141-8001
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Marquié, Marta|||0000-0002-0660-0950
  • Castoldi, Massimo
  • Cordioli, Mattia|||0000-0002-4872-0520
  • Cecconi, Maurizio|||0000-0002-4376-6538
  • D'Amato, Mauro
  • Augustin, Max|||0000-0002-2300-9337
  • Tomasi, Melissa
  • Boada, Mercè|||0000-0003-2617-3009
  • Dreher, Michael
  • Seilmaier, Michael J.
  • Joannidis, Michael
  • Wittig, Michael
  • Mazzocco, Michela
  • Ciccarelli, Michele|||0000-0003-2379-1960
  • Rodríguez-Gandía, Miguel
  • Bocciolone, Monica
  • Miozzo, Monica
  • Imaz Ayo, Natale|||0000-0001-9087-901X
  • Blay, Natalia|||0000-0002-7160-8529
  • Chueca, Natalia|||0000-0002-3420-3290
  • Montano, Nicola
  • Braun, Nicole
  • Ludwig, Nicole|||0000-0003-4703-7567
  • Marx, Nikolaus
  • Martínez, Nilda
  • Cornely, Oliver A.|||0000-0001-9599-3137
  • Witzke, Oliver
  • Palmieri, Orazio
  • Faverio, Paola|||0000-0002-0360-1237
  • Preatoni, Paoletta
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Omodei, Paolo
  • Tentorio, Paolo
  • Castro Rebollo, Pedro|||0000-0002-6118-8970
  • Rodrigues, Pedro M.
  • España, PP.|||0000-0001-5723-8253
  • Hoffmann, Per|||0000-0002-6573-983X
  • Rosenstiel, Philip|||0000-0002-9692-8828
  • Schommers, Philipp
  • Suwalski, Phillip
  • de Pablo, Raúl
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Bals, Robert
  • Gualtierotti, Roberta
  • Gallego-Durán, Rocío
  • Nieto, Rosa
  • Carpani, Rossana
  • Morilla, Rubén
  • Badalamenti, Salvatore
  • Haider, Sammra
  • Ciesek, Sandra
  • May, Sandra
  • Bombace, Sara
  • Marsal, Sara|||0000-0001-5515-3854
  • Pigazzini, Sara
  • Klein, Sebastian
  • Pelusi, Serena
  • Wilfling, Sibylle
  • Bosari, Silvano
  • Volland, Sonja
  • Brunak, Søren|||0000-0003-0316-5866
  • Raychaudhuri, Soumya|||0000-0002-1901-8265
  • Schreiber, Stefan
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Aliberti, Stefano|||0000-0002-0090-4531
  • Ripke, Stephan|||0000-0003-3622-835X
  • Dudman, Susanne|||0000-0001-5047-4982
  • Wesse, Tanja
  • Zheng, Tenghao
  • Bahmer, Thomas
  • Eggermann, Thomas
  • Illig, Thomas
  • Brenner, Thorsten
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Feldt, Torsten
  • Folseraas, Trine
  • Gonzalez Cejudo, Trinidad
  • Landmesser, Ulf
  • Protzer, Ulrike|||0000-0002-9421-1911
  • Hehr, Ute
  • Rimoldi, Valeria
  • Monzani, Valter
  • Skogen, Vegard
  • Keitel, Verena
  • Kopfnagel, Verena
  • Friaza, Vicente|||0000-0002-2900-4334
  • Andrade, Victor|||0000-0003-0682-269X
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Morros, Rosa|||0000-0001-6752-8748
  • Albrecht, Wolfgang
  • Peter, Wolfgang
  • Poller, Wolfgang
  • Farré Ramon, Xavier|||0000-0001-6838-9479
  • Yi, Xiaoli
  • Wang, Xiaomin
  • Khodamoradi, Yascha|||0000-0001-5972-0967
  • Karadeniz, Zehra
  • Latiano, Anna
  • Goerg, Siegfried
  • Bacher, Petra
  • Koehler, Philipp|||0000-0002-7386-7495
  • Tran, Florian
  • Zoller, Heinz|||0000-0003-1794-422X
  • Schulte, Eva C.|||0000-0003-3105-5672
  • Heidecker, Bettina
  • Ludwig, Kerstin U.|||0000-0002-8541-2519
  • Fernández, Javier|||0000-0002-5622-0489
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Albillos, Agustín|||0000-0001-9131-2592
  • Invernizzi, Pietro|||0000-0003-3262-1998
  • Buti, Maria|||0000-0002-0732-3078
  • Duga, Stefano
  • Bujanda, Luis|||0000-0002-4353-9968
  • Hov, Johannes R.|||0000-0002-5900-8096
  • Lenz, Tobias L.
  • Asselta, Rosanna
  • de Cid, Rafael|||0000-0003-3579-6777
  • Valenti, Luca|||0000-0001-8909-0345
  • Karlsen, Tom H.
  • Cáceres Aguilar, Mario|||0000-0002-7736-3251
  • Franke, Andre|||0000-0003-1530-5811
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended genome-wide association meta-analysis of a well-characterized cohort of 3255 COVID-19 patients with respiratory failure and 12 488 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a ~0.9-Mb inversion polymorphism that creates two highly differentiated haplotypes and characterized the potential effects of the inversion in detail. Our data, together with the 5th release of summary statistics from the COVID-19 Host Genetics Initiative including non-Caucasian individuals, also identified a new locus at 19q13.33, including NAPSA, a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis, A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

  • Ampuero, Javier|||0000-0002-8332-2122
  • Aller, Rocio
  • Gallego-Durán, Rocío
  • Crespo García, Javier|||0000-0001-8248-0172
  • Abad, Javier
  • González-Rodríguez, Águeda|||0000-0001-6428-6210
  • Gómez-Camarero, Judith
  • Caballería, Joan
  • Lo Iacono, Oreste
  • Ibáñez Samaniego, Luis|||0000-0002-0309-2727
  • García-Samaniego, Javier|||0000-0002-9974-0855
  • Martín-Mateos, Rosa
  • Francés, Rubén
  • Fernández-Rodríguez, Conrado
  • Diago, Moises|||0000-0002-8583-2433
  • Soriano, German|||0000-0002-9267-6811
  • Andrade, Raúl J.
  • Latorre, Raquel
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Escudero-García, Desamparados
  • Estévez, Pamela
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Pareja-Megia, María Jesús
  • Banales, Jesus|||0000-0002-5224-2373
  • Aspichueta, Patricia
  • Benlloch, Salvador|||0000-0002-0794-6937
  • Rosales, José Miguel
  • Salmerón, Javier
  • Turnes, Juan|||0000-0001-8426-6145
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
Background and Aim: Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We assessed the NASH distribution and its components across the fibrosis stages and their impact on the prognosis and their relationship with the concept of metabolic-associated fatty liver disease (MAFLD). Methods: Spanish multicenter study including 1893 biopsy-proven nonalcoholic fatty liver disease (NAFLD) patients from HEPAmet registry. NASH was diagnosed by NAS score ≥4 (including steatosis, ballooning and lobular inflammation) and fibrosis by Kleiner score. The presence of MAFLD was determined. Progression to cirrhosis, first episode of decompensated cirrhosis and death were collected during the follow-up (4.7 ± 3.8 years). Results: Fibrosis was F0 34.3% (649/1893), F1 27% (511/1893), F2 16.5% (312/1893), F3 15% (284/1893) and F4 7.2% (137/1893). NASH diagnosis 51.9% (982/1893), and its individual components (severe steatosis, ballooning and lobular inflammation), increased from F0 (33.6%) to F2 (68.6%), and decreased significantly in F4 patients (51.8%) (P =.0001). More than 70% of non-NASH patients showed some inflammatory activity (ballooning or lobular inflammation), showing a similar MAFLD rate than NASH (96.2% [945/982] vs. 95.2% [535/562]) and significantly higher than nonalcoholic fatty liver (NAFL) subjects (89.1% [311/349]) (P <.0001). Progression to cirrhosis was similar between NASH (9.5% [51/539]) and indeterminate NASH (7.9% [25/316]), and higher than steatosis (5% [14/263]) (logRank 8.417; P =.015). Death and decompensated cirrhosis were similar between these. Conclusions: The prevalence of steatohepatitis decreased in advanced liver disease. However, most of these patients showed some inflammatory activity histologically and had metabolic disturbances. These findings should be considered in clinical trials whose main aim is to prevent cirrhosis progression and complications, liver transplant and death.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients

  • Gil-Gómez, Antonio
  • Rojas, Ángela|||0000-0003-0853-4800
  • García-Lozano, María R.
  • Muñoz-Hernández, Rocío
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Montero-Vallejo, Rocío
  • Gato, Sheila
  • Gallego, Javier
  • Francés, Rubén
  • Soriano, German|||0000-0002-9267-6811
  • Ampuero, Javier|||0000-0002-8332-2122
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced fibrosis and cirrhosis. In this study, we aimed to evaluate the prognosis of cirrhotic patients harboring this variant. We performed a retrospective analysis on 483 prospectively recruited patients from four different hospitals in Spain, followed-up for at least 5 years. We collected clinical, demographic, and biochemical data, and we performed a genotyping analysis for common variants previously associated with liver disease risk (HSD17B13 rs72613567:TA and PNPLA3 rs738409). Patients homozygous for the TA allele showed a higher MELD score (p = 0.047), Child-Turcotte-Pugh score (p = 0.014), and INR levels (p = 0.046), as well as decreased albumin (p = 0.004) at baseline. After multivariate analysis, patients with the "protective" variant indeed had an increased risk of hepatic decompensation [aHR 2.37 (1.09-5.06); p = 0.029] and liver-related mortality [aHR 2.32 (1.20-4.46); p = 0.012]. Specifically, these patients had an increased risk of developing ascites (Log-R 11.6; p < 0.001), hepatic encephalopathy (Log-R 10.2; p < 0.01), and higher mortality (Log-R 14.1; p < 0.001) at 5 years of follow-up. Interactions with the etiology of the cirrhosis and with the variant rs738409 in PNPLA3 are also described. These findings suggest that the variant rs72613567:TA in HSD17B13 has no protective effect, but indeed increases the risk of decompensation and death in patients with advanced chronic liver disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

  • Ampuero, Javier|||0000-0002-8332-2122
  • Aller, Rocio
  • Gallego-Durán, Rocío
  • Crespo García, Javier|||0000-0001-8248-0172
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • García-Monzón, Carmelo
  • Gómez-Camarero, Judith
  • Caballería, Joan
  • Lo Iacono, Oreste
  • Ibáñez Samaniego, Luis|||0000-0002-0309-2727
  • García-Samaniego, Javier|||0000-0002-9974-0855
  • Albillos, Agustín|||0000-0001-9131-2592
  • Francés, Rubén
  • Fernández-Rodríguez, Conrado
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Diago, Moises|||0000-0002-8583-2433
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Andrade, Raúl J.
  • Latorre, Raquel
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Escudero-García, Desamparados
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Pareja-Megia, María Jesús
  • Banales, Jesus|||0000-0002-5224-2373
  • Aspichueta, Patricia
  • Benlloch, Salvador|||0000-0002-0794-6937
  • Rosales, José Miguel
  • Turnes, Juan|||0000-0001-8426-6145
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
Background: MASLD can manifest as hepatocellular damage, which can result in mild elevation of aminotransferases. However, in some patients, MASLD presents with cholestatic pattern. Objective: To assess the impact of the biochemical pattern on the natural course of MASLD, including liver damage in histology, the accuracy of non-invasive tests(NITs), and prognosis. Methods: Multicenter study enrolling 2156 patients with biopsy-proven MASLD, who were classified based on their[ALT/ULN)]/[(ALP/ULN)] levels at the time of biopsy: (a) hepatocellular pattern(H),.